Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer
2022-06-30
عنوان الدراسة
Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer
داعم الدراسة
AstraZeneca
دواء الدراسة
Paclitaxel
رقم بروتوكول الدراسة
ESR-14-10649
حالة الدراسة
Ongoing
موقع الدراسة
KFSH & RC-R
مرحلة الدراسة
1
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。